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Background/Aims: Endoscopic ultrasonography (EUS) is warranted when cross-sectional imaging demonstrates common bile duct
(CBD) dilatation without identifiable causes. This study aimed to assess the diagnostic performance of EUS in CBD dilatation of
unknown etiology.
Methods: Retrospective review of patients with dilated CBD without definite causes undergoing EUS between 2012 and 2017.
Results: A total of 131 patients were recruited. The mean age was 63.2±14.1 years. The most common manifestation was abnormal
liver chemistry (85.5%). The mean CBD diameter was 12.2±4.1 mm. The area under the receiver operating characteristic curve
(AUROC) of EUS-identified pathologies, including malignancy, choledocholithiasis, and benign biliary stricture (BBS), was 0.98
(95% confidence interval [CI], 0.95-1.00). The AUROC of EUS for detecting malignancy, choledocholithiasis, and BBS was 0.91
(95% CI, 0.85-0.97), 1.00 (95% CI, 1.00-1.00), and 0.93 (95% CI, 0.87-0.99), respectively. Male sex, alanine aminotransferase ≥3× the
upper limit of normal (ULN), alkaline phosphatase ≥3× the ULN, and intrahepatic duct dilatation were predictors for pathological
obstruction, with odds ratios of 5.46 (95%CI, 1.74-17.1), 5.02 (95% CI, 1.48-17.0), 4.63 (95% CI, 1.1-19.6), and 4.03 (95% CI, 1.3711.8), respectively.
Conclusions: EUS provides excellent diagnostic value in identifying the etiology of CBD dilatation detected by cross-sectional
imaging. Clin Endosc 2022;55:122-127
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INTRODUCTION
Cross-sectional imaging, including multi-detector computed tomography (MDCT), magnetic resonance imaging (MRI),
and magnetic resonance cholangiopancreatography (MRCP),
have been widely used to evaluate the pancreaticobiliary sys-
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tem. In detecting pancreatic and biliary disease, MDCT and
MRI have a sensitivity of 70%–95% and 85%–96% and a specificity of 75%–85% and 89%–98%, respectively.1-5 Despite their
excellent diagnostic performance, the evaluation of the distal
bile duct or ampullary area is often limited. In asymptomatic
patients, dilated common bile ducts (CBDs) on imaging may
be influenced by age, sex, body mass index, and cholecystectomy history. The common pathological causes of CBDs
dilatation are choledocholithiasis, periampullary carcinoma,
and benign biliary stricture (BBS); however, these lesions can
be missed by MDCT, MRI, and MRCP.6-12 Endoscopic retrograde cholangiopancreatography (ERCP) has historically been
one of the most accurate diagnostic procedures for pancreatic
and biliary diseases. However, it should only be done for therapeutic purposes due to its invasive nature and potential lethal
complications, such as post-ERCP pancreatitis, bleeding, and
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perforation. Endoscopic ultrasonography (EUS) has evolved
as a tool for evaluating hepatobiliary and pancreatic diseases.
There is a dearth of literature regarding the utility of EUS in
outlining a dilated CBDs.13 This study aimed to evaluate the
diagnostic yield of EUS in dilated CBDs without identifiable
causes on MDCT or MRI with or without MRCP findings.

symptoms during a 12-month follow-up of clinical condition,
laboratory, and radiological studies. If surgical pathology was
available, BBS was defined as the absence of malignancy. CBDs
dilatation without pathological causes was determined by
the absence of progression of bile duct dilatation and interval
symptoms during a 12-month follow-up of clinical condition,
laboratory, and radiological studies.

MATERIALS AND METHODS

Statistical analysis

Study population

The 2012–2017 EUS database at a tertiary care center was
retrospectively reviewed. The study protocol was approved by
the institutional review board and was adapted to the ethical
guidelines of the Declaration of Helsinki. Patients who underwent EUS due to CBDs dilatation without definite etiology
detected by MDCT or MRI with or without MRCP were
identified. The inclusion criteria were as follows: 1) CBDs dilatation, defined as CBDs diameter ≥7 mm in patients with gall
bladder in situ or ≥10 mm in post-cholecystectomy patients
and 2) no causes of CBDs dilatation identified by MDCT or
MRI with or without MRCP. The exclusion criteria were as
follows: 1) patients with definite causes of CBDs dilatation
identified by cross-sectional imaging and 2) patients without
available MDCT, MRI, or MRCP for review.

Clinical, laboratory, and radiological data

All EUS procedures were performed with either a radial
(GF-UE160-AL5; Olympus, Tokyo, Japan) or linear (GFUC140P-AL5; Olympus, Tokyo, Japan) echoendoscope by
an experienced endoscopist who had performed more than
2,000 EUS procedures. Demographic data, clinical presentations, laboratory results, radiological findings, EUS findings,
cytopathological results, and follow-up data of all included
patients were collected. The definite diagnosis was determined
by the results of ERCP, cytology, or histology obtained from
EUS-guided tissue acquisition (EUS-TA), surgical pathology,
and clinical, laboratory, and radiological follow-up for at least
12 months.

Definition

Choledocholithiasis was determined by visualization of the
stones in the CBDs during ERCP. Malignancy was confirmed
by cytology or histology obtained by EUS-TA, or surgical pathology. If the tissue diagnosis could not be obtained, clinical,
laboratory, and radiological follow-up was required for at least
12 months. BBS was defined as narrowing of the distal CBDs
diameter without visualization of stones or masses and negative cytology or histology obtained by EUS-TA or ERCP, combined with no progression of bile duct dilatation and interval

Descriptive statistics were computed for demographic,
clinical, and laboratory data. For normally distributed quantitative variables, results are expressed as means and standard
deviations; otherwise, medians and ranges are reported. Qualitative variables were summarized as counts and percentages.
The area under the receiver operating characteristic curve
(AUROC) was calculated to evaluate the overall accuracy
of EUS for identifying the causes of bile duct dilatation. The
predictive ability was further analyzed by calculating the sensitivity, specificity, positive likelihood ratio, negative likelihood
ratio, positive predictive value (PPV), and negative predictive
value (NPV) with their 95% confidence interval (CI)s. Logistic regression models were used to evaluate the relationship
between baseline characteristics and the presence or absence
of pathology. All statistical tests were performed at the conventional two-tailed α-level of 0.05. SPSS Statistics (version 18.0;
SPSS Inc., Chicago, IL, USA) was used for all analyses.

RESULTS
Characteristics of the study cohort

The EUS database showed that 2,954 patients underwent
diagnostic EUS during the study period. A total of 175 patients underwent EUS for CBDs dilatation without identifiable
causes. Forty-four patients were excluded because of unavailable radiological studies for review. Among the 131 included
patients, the mean age was 63.2± 14.1 years, 47.3% were male,
and the most common clinical manifestations were abnormal
liver function tests (85.5%), jaundice (48.9%), and abdominal
pain (48.1%). The mean CBDs diameter was 12.2 ±4.1 mm,
and 58% had coexisting intrahepatic duct (IHD) dilatation.
Among abnormal liver function tests, elevated total bilirubin
(median, 2.3 mg/dL; range, 0.2–37.8), aspartate aminotransferase (median, 66 IU/L), alanine aminotransferase (ALT)
(median, 66 IU/L), and alkaline phosphatase (ALP) (median,
249 IU/L) were detected (Table 1).

Definite etiology of CBD dilatation

EUS detected the causes of CBDs dilatation in 88 of 131
patients (67%). Among the 131 patients, 41 patients (31%) had
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Table 1. Baseline Characteristics of the Study Population

Baseline Characteristics

Values

Number

131

Male gender

62 (47.3)

Age (years)

63.2±14.1
2

Body mass index (kg/m )

21.8±3.5

History of cholecystectomy

19 (14.5)

Clinical presentation
Abnormal liver function test

112 (85.5)

Jaundice

64 (48.9)

Abdominal pain

63 (48.1)

Fever

19 (14.5)

Constitutional symptoms

19 (14.5)

Weight loss

29 (22.1)

Palpable gallbladder

5 (3.8)

Laboratory finding
AST (IU/L)

66 (7–611)

ALT (IU/L)

66 (7–611)

ALP (IU/L)

249 (28–1,630)

Gamma glutamyl transpeptidase (IU/L)

445 (35–1,906)

Total bilirubin (mg/dL)

2.3 (0.2–37.8)

CA 19-9 (IU/L)

62.9 (20–52,843)

Imaging findings
Common bile duct diameter (mm)

12.2±4.1

Intrahepatic duct dilatation

77 (58.8)

Intraabdominal lymphadenopathy

14 (10.7)

Chronic pancreatitis

6 (4.6)

Data are presented as the number (%) or mean±standard deviation.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; CA, carbohydrate antigen.

malignancy, consisting of distal cholangiocarcinoma (51.2%),
ampullary adenocarcinoma (24.3%), pancreatic adenocarcinoma 19.5%), gallbladder carcinoma (2.5%), and duodenal adenocarcinoma (2.5%). A total of 24 (18.3%), 23 (17.6%), and 43
(33%) patients had choledocholithiasis, BBS, and dilated CBDs
without a pathological cause of obstruction, respectively.

Diagnostic performance of EUS

The diagnostic performance of EUS in detecting the causes
of CBDs dilatation was evaluated, as shown in Table 2. EUS
had an excellent diagnostic performance for identifying the
etiology of CBDs dilatation with an AUROC, sensitivity,
specificity, PPV, and NPV of 0.98 (95% CI, 0.95–1.00), 100%
(95% CI, 95.8–100), 95.6% (95% CI, 84.9–99.5), 97.7% (95%
CI, 92.0–99.7), and 100% (95% CI, 91.8–100), respectively.
Furthermore, we assessed the diagnostic accuracy of EUS for
each diagnosis. Among all the diagnoses, EUS performed the
best in detecting choledocholithiasis with an AUROC, sensitivity, and specificity of 1.00 (95% CI, 1.00–1.00), 100% (95%
CI, 85.8–100), and 100% (95% CI, 96.6–100), respectively.
For malignancy, EUS was 82.9% (95% CI, 67.9–92.8) sensitive
and 98.9% (95% CI, 94.0–100) specific with an AUROC of
0.91 (95% CI, 0.85–0.97). For BBS, EUS had an AUROC of
0.93 (95% CI, 0.87–0.99) with a high NPV of 98.1% (95% CI,
93.2–99.8).

Predictors for determining the presence of
pathological obstruction

Multivariate analysis showed that male sex, ALT ≥ 3 × the
upper limit of normal (ULN), ALP ≥ 3 × the ULN, and IHD
dilatation were significant predictors for pathological obstruction, with odds ratios of 5.46 (95% CI, 1.74–17.1), 5.02 (95%
CI, 1.48–17.0), 4.63 (95% CI, 1.1–19.6) and 4.03 (95% CI,
1.37–11.8), respectively (Table 3).

Table 2. Diagnostic Performance of Endoscopic Ultrasonography for Identifying Causes of Common Bile Duct Dilatation

Definite diagnosis

AUROC
(95% CI)

Sensitivity (95% CI) Specificity (95% CI)

LR+
(95% CI)

LR(95% CI)

PPV
(95% CI)

NPV
(95% CI)

Pathological obstruction

0.98
(0.95–1.00)

100
(95.8–100)

95.6
(84.9–99.5)

22.5
(5.81–87.2)

0

97.7
(92.0–99.7)

100
(91.8–100)

Choledocholithiasis

1.00
(1.00–1.00)

100
(85.8–100)

100
(96.6–100)

–

0

100
(85.8–100)

100
(96.6–100)

Malignancy

0.91
(0.85–0.97)

82.9
(67.9–92.8)

98.9
(94.0–100)

74.6
(10.6–527)

0.17
(0.09–0.34)

97.1
92.7
(85.1–99.9) (85.6–97.0)

Benign biliary stricture

0.93
(0.87–0.99)

91.7
(73.0–99.0)

94.4
(88.3–97.9)

16.5
(751–36.2)

0.09
(0.02–0.33)

78.6
98.1
(59.0–91.7) (93.2–99.8)

AUROC, area under the receiver operating characteristic curve; CI, confidence interval; LR+, positive likelihood ratio; LR-, negative likelihood ratio; NPV, negative predictive value; PPV, positive predictive value.
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Table 3. Predictive Factors for Pathological Obstruction and No Pathological Lesion Among Patients with Common Bile Duct Dilatation

Variables

Univariate analysis

Multivariate analysis

OR (95% CI)

p-value

OR (95% CI)

p-value

Male gender

4.10 (1.79–8.97)

0.001

5.46 (1.74–17.1)

0.004

History of cholecystectomy

0.38 (0.14–1.01)

0.052

Jaundice

20.9 (6.80–64.2)

<0.001

Abdominal pain

2.24 (1.05–4.76)

0.036

Fever

10.8 (1.39–83.9)

0.023

Constitutional symptoms

4.91 (1.18–22.3)

0.040

Total bilirubin >5 mg/dL

5.41 (2.05–14.3)

0.001

AST >3 x ULN

2.57 (1.06–6.27)

0.038

ALT >3 x ULN

4.06 (1.62–10.2)

0.003

5.02 (1.48–17.0)

0.009

ALP >3 x ULN

8.17 (2.33–28.7)

0.001

4.63 (1.10–19.6)

0.037

Intrahepatic biliary dilatation

2.83 (1.33–5.99)

0.007

4.03 (1.37–11.8)

0.011

Intraabdominal lymphadenopathy

7.36 (0.92–58.8)

0.060

Pathological obstruction

ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; OR, odds ratio; ULN,
upper limit of normal

DISCUSSION
CBDs dilatation without a discernible cause is not an unexpected finding on cross-sectional imaging. EUS is generally performed in cases of unexplained CBDs dilatation to
evaluate the distal bile duct and ampullary area. Nonetheless,
evidence-based guidelines have not been established for this
clinical setting because of a lack of data. Retrospective studies
have evaluated the diagnostic yield of EUS for causes of dilated
CBDs, particularly in asymptomatic patients with unexplained
CBDs dilatation with both normal and elevated serum liver
enzymes.6,8,12,14,15 EUS was able to detect bile duct pathologies,
including dilated CBDs with no obvious etiology, in cross-sectional imaging studies of 6%–21% of asymptomatic patients
with normal liver chemistry.8,14,15 For those with combined
CBDs dilatation and abnormal liver chemistry, 50%–100% had
pathologies detected by EUS.12,15 These results emphasized the
importance of EUS in this setting; nonetheless, the diagnostic
accuracy is yet to be explored.
In the current study, approximately 50% of the patients were
symptomatic, and the majority had abnormal liver chemistry.
EUS detected bile duct pathologies in 67% of the patients with
inconclusive MDCT or MRI with or without MRCP, and the
diagnostic performance of EUS in detecting pathologic lesions
was excellent, with an AUROC of 0.98. In contrast to other
studies, the most common pathologic etiology in our study

was malignant obstruction, accounting for one-third of the
cohort, with distal cholangiocarcinoma being found in 51%.
Choledocholithiasis was the second most common etiology,
accounting for 18.3%, while most studies showed that choledocholithiasis was the most common cause, with rates up
to nearly 40%, followed by malignancy. We hypothesized that
the discrepancy between our results and those of other studies
could be attributed to the differences in patient characteristics,
including presenting symptoms and the degree of liver chemistry abnormalities. Studies in asymptomatic patients with normal liver chemistry have demonstrated a lower percentage of
abnormalities and malignancies detected by EUS. In contrast,
49% of our patients presented with jaundice and a mean total
bilirubin level of 5 mg/dL, suggesting underlying pathological
bile duct obstruction. Furthermore, the most common malignancy was distal cholangiocarcinoma, which could be difficult
to identify using a MDCT scan or MRI. EUS has increasingly
become the imaging tool of choice of malignant etiology in dilated CBDs due to its high sensitivity and accuracy, especially
in patients with distal biliary obstruction.16,17 Prior studies have
reported a sensitivity of EUS in detecting biliary malignancy,
including hilar cholangiocarcinoma, ranging from 40%–
90%.18-20 In addition, there has been a report of EUS detection
of distal CBD tumor, whereas CT scan and MRCP suggested
stone formation.21 The current study underscores the excellent
diagnostic performance of EUS in diagnosing malignancy as a
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cause of bile duct dilatation with an AUROC of 0.91 and specificity of 98.9%.
The exceptional diagnostic accuracy of EUS in detecting
choledocholithiasis has been widely accepted. Although EUS
and MRCP were comparable in terms of sensitivity, specificity, and accuracy for detecting choledocholithiasis,22 EUS has
detected very small choledocholithiasis missed by MDCT and
MRCP with 100% diagnostic accuracy, avoiding unnecessary
ERCP and surgery.21,23 Scheiman et al.24 suggested that implementing the initial EUS strategy to evaluate patients with
suspected biliary disease had the greatest cost-utility, resulting
in less unnecessary ERCPs and ERCP-related complications.24
Similarly, our results showed that EUS performed the best in
detecting choledocholithiasis with the AUROC of 1.0. It is important to point out that EUS detection of choledocholithiasis
has been reported in CBDs dilatation of unknown etiology in
patients with both normal and abnormal liver chemistry, highlighting the necessity of EUS in managing this clinical scenario. Factors that may help predict pathological obstruction are
male sex, serum ALT level ≥3 × the ULN, serum ALP ≥ 3 ×
the ULN, and IHD dilatation. Thus, when the dilated bile duct
was noted on cross-sectional imaging along with the above
parameters, further investigation with EUS is warranted. In
contrast, clinical follow-up without further invasive investigations might be sufficient in patients without these parameters.
Oppong et al.14 reported that a history of cholecystectomy,
which was identified in 36% of the cases, is a causative factor
for non-obstructive CBDs dilatation. In contrast, only 14% of
our patients had prior cholecystectomy.
This study was limited by its retrospective nature and the
need to use clinical follow-up as part of the definite diagnosis
instead of undergoing ERCP or surgery in all cases. However,
the strength of the study was high-quality radiologic imaging
in all recruited patients and a long-term follow-up of at least
12 months.
In conclusion, EUS is a useful modality for evaluating CBDs
dilatation in inconclusive MDCT, MRI, or MRCP. It should be
routinely performed for clinically or biochemically indicated
pancreatobiliary diseases. The excellent diagnostic performance of EUS could help avoid unnecessary ERCP or surgery
in clinical practice.
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